A Study of Soticlestat Tablets in Healthy Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-11

Study Completion Date

2022-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim is to see how soticlestat tablets of different strengths work and to compare how it works alone in contrast to administration along with food.

In the study will be 2 groups of participants (part A and part B). Participants in part A will receive 300 mg of soticlestat administered in different kind of tablets (regular tablets, mini-tablets, commercial tablets) and participant in part B will also receive 300 mg of soticlestat in tablets but with food and crushed tablets with applesauce.

Participants will complete several assessments including clinical laboratory evaluations, physical examinations, Columbia-Suicide Severity Rating Scale (C-SSRS) assessment, electrocardiographs (ECGs), and vital signs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants

NCT05048784

Healthy Participants

COMPLETED PHASE1

A Study of Seltorexant in Healthy Participants

NCT04553042

Healthy

COMPLETED PHASE1

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

NCT03042299

Japanese Healthy Adult Male Participants

COMPLETED PHASE1

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT03340753

Bioequivalence

COMPLETED PHASE1

A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

NCT02372097

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called soticlestat (TAK-935). The study will assess the bioequivalence, effect of food and tablet crushing, safety and tolerability following single oral dose of 3 different soticlestat oral tablet formulations in healthy participants.

The study will enroll approximately 96 participants. This study will be conducted in two parts (Part A and Part B) having 6 treatment sequences each. Participants will be randomly assigned (by chance, like flipping a coin) to one of the study parts as per treatment sequence:

* Part A, Sequence 1: Treatment A + Treatment B + Treatment C
* Part A, Sequence 2: Treatment A + Treatment C + Treatment B
* Part A, Sequence 3: Treatment B + Treatment A + Treatment C
* Part A, Sequence 4: Treatment B + Treatment C + Treatment A
* Part A, Sequence 5: Treatment C + Treatment A + Treatment B
* Part A, Sequence 6: Treatment C + Treatment B + Treatment A
* Part B, Sequence 1: Treatment D + Treatment E + Treatment F
* Part B, Sequence 2: Treatment D + Treatment F + Treatment E
* Part B, Sequence 3: Treatment E + Treatment D + Treatment F
* Part B, Sequence 4: Treatment E + Treatment F + Treatment D
* Part B, Sequence 5: Treatment F + Treatment D + Treatment E
* Part B, Sequence 6: Treatment F + Treatment E + Treatment D

This single center trial will be conducted in the United States. The overall duration of the study is approximately 51 days. Participants will be followed up for 14 days after the last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A, Sequence 1: Treatment A + Treatment B + Treatment C

Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part A, Sequence 2: Treatment A + Treatment C + Treatment B

Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part A, Sequence 3: Treatment B + Treatment A + Treatment C

Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part A, Sequence 4: Treatment B + Treatment C + Treatment A

Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part A, Sequence 5: Treatment C + Treatment A + Treatment B

Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part A, Sequence 6: Treatment C + Treatment B + Treatment A

Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 1: Treatment D + Treatment E + Treatment F

Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 2: Treatment D + Treatment F + Treatment E

Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 3: Treatment E + Treatment D + Treatment F

Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 4: Treatment E + Treatment F + Treatment D

Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 5: Treatment F + Treatment D + Treatment E

Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Part B, Sequence 3: Treatment F + Treatment E + Treatment D

Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat T4 tablets.

Soticlestat

Intervention Type DRUG

Soticlestat T3 mini-tablets.

Soticlestat

Intervention Type DRUG

Soticlestat commercial tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soticlestat

Soticlestat T4 tablets.

Intervention Type DRUG

Soticlestat

Soticlestat T3 mini-tablets.

Intervention Type DRUG

Soticlestat

Soticlestat commercial tablets.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAK-935 TAK-935 TAK-935

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Body mass index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 32.0 kilogram per square meter (kg/m\^2) at screening.
2. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing.
3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, and ECGs, as deemed by the Investigator or designee.
4. Able to swallow multiple tablets.

Exclusion Criteria

1. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
2. Positive urine drug or alcohol results at screening or check-in.
3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
4. Unable to refrain from or anticipates the use of:

* Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to the first dosing.
* Any drugs known to be significant inducers of cytochrome P450 (CYP) 3A, CYP2C19, uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A9 or UGT2B4 enzymes and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the first dosing. Appropriate sources will be consulted to confirm lack of PK/pharmacodynamics interaction with study drug.
5. History of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer \[354 milliliter per 12 ounce {mL/12 oz}\], wine \[118 mL/4 oz\], or distilled spirits \[29.5 mL/1 oz\] per day).
6. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
7. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
8. Donation of blood or significant blood loss within 56 days prior to the first dosing.
9. Plasma donation within 7 days prior to the first dosing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes